Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):534-40. doi: 10.1016/j.clml.2013.04.011. Epub 2013 Jun 10.
Primary cutaneous lymphoma (PCL) comprises a heterogeneous group of diseases in regard to clinical presentation, histologic appearance, and biological behavior. Its rare occurrence limits analysis of disease features and survival of patients.
All patients with PCL treated in our hospital during January 2006 to October 2012 were included in this retrospective study. Their histologic and clinical data were analyzed. The diagnosis of PCL and the evaluation of clinical behavior were based on the 2005 World Health Organization-European Organisation for Research and Treatment of Cancer (WHO-EORTC) classification.
Fifty-four cases of PCL were included in the study. The median age was 52.5 years. Thirteen (24.1%) patients had B-cell lymphoma and 41 (75.9%) had T-cell lymphoma. Twenty-nine (53.7%) patients exhibited disease having indolent clinical behavior, 14 (25.9%) presented with B symptoms, and 16 (29.6%) had elevated lactate dehydrogenase (LDH) levels at baseline. Within a median follow-up of 47.8 months, the expected 5-year progression-free survival (PFS) rate and overall survival (OS) rate were 6% and 14%, respectively. Using multivariate analysis, aggressive behavior (hazard ratio [HR], 2.92; P = .01] and elevated LDH levels at baseline (HR, 2.88; P = .01) were identified as independent risk factors for PFS. In addition, aggressive behavior (HR, 4.09; P = .01) and elevated LDH levels at baseline (HR, 3.69; P = .01) were also identified as independent risk factors for OS.
The study data suggest that aggressive behavior and elevated LDH levels at baseline were predictive factors for poor PFS and OS, which supports the need for immediate treatment of those patients.
原发性皮肤淋巴瘤(PCL)在临床表现、组织学表现和生物学行为方面均存在异质性。由于其罕见性,限制了对疾病特征和患者生存的分析。
本回顾性研究纳入了 2006 年 1 月至 2012 年 10 月期间在我院接受治疗的所有 PCL 患者。分析了他们的组织学和临床数据。PCL 的诊断和临床行为评估基于 2005 年世界卫生组织-欧洲癌症研究与治疗组织(WHO-EORTC)分类。
本研究共纳入 54 例 PCL 患者。中位年龄为 52.5 岁。13 例(24.1%)患者为 B 细胞淋巴瘤,41 例(75.9%)为 T 细胞淋巴瘤。29 例(53.7%)患者表现为惰性临床行为,14 例(25.9%)有 B 症状,16 例(29.6%)基线乳酸脱氢酶(LDH)水平升高。中位随访 47.8 个月后,预期 5 年无进展生存(PFS)率和总生存(OS)率分别为 6%和 14%。多因素分析显示,侵袭性行为(风险比[HR],2.92;P =.01)和基线 LDH 水平升高(HR,2.88;P =.01)是 PFS 的独立危险因素。此外,侵袭性行为(HR,4.09;P =.01)和基线 LDH 水平升高(HR,3.69;P =.01)也是 OS 的独立危险因素。
研究数据表明,侵袭性行为和基线 LDH 水平升高是 PFS 和 OS 不良的预测因素,这支持对这些患者进行即刻治疗的必要性。